Results
cancer
CANCER
A total of 65 patients enrolled in the study. Of these, 62 received treatment (mean age [standard deviation (SD)], 61.0 [11.7] years; 40 [64.5%] women; Table The most common (≥ 10% of patients) primary diagnoses were lung (24.2%), ovarian (21.0%) and uterine (12.9%) cancer in 15, 13 and 8 patients, respectively.All patients received antiemetics during the study. Of these, 49 (79.0%) patients received serotonin 5-HT3 antagonists (granisetron, granisetron hydrochloride, ondansetron, ondansetron hydrochloride, palonosetron hydrochloride) and 48 (77.4%) patients received glucocorticoids (dexamethasone, fluticasone propionate, hydrocortisone, methylprednisolone, prednisolone, prednisone).Seventeen (27.4%) patients took prohibited concomitant medication during study treatment. No important protocol deviations were reported.